使用N-乙酰半胱氨酸联合西甲硅油改善上消化道内镜检查中黏膜可见度:一项双盲随机对照试验
这项双盲随机对照试验纳入230例患者,比较无干预、水100mL、西甲硅油200mg、西甲硅油联合N-乙酰半胱氨酸500mg或1000mg在检查前20分钟口服对胃黏膜可见度的影响。结果显示联合N-乙酰半胱氨酸500mg和1000mg组可见度充分率分别为65%和67%,高于无干预组44%(P=0.044)和水组41%(P=0.022);单用西甲硅油与对照组无差异,联合1000mg组所需用水量更少,未观察到药物不良反应。
要点
- 检查前20分钟口服西甲硅油联合N-乙酰半胱氨酸500mg或1000mg可提高上消化道内镜胃黏膜可见度。
- 单用西甲硅油200mg在改善胃可见度方面与无干预和水组无差异。
- 联合N-乙酰半胱氨酸1000mg组改善可见度所需用水量更少,且未观察到药物不良反应。
核心结论
- 检查前口服西甲硅油联合N-乙酰半胱氨酸500mg和1000mg可改善上消化道内镜的胃黏膜可见度,而单用西甲硅油未显示改善胃可见度。
研究设计与样本
- 随机双盲安慰剂对照试验,设2个对照组(无干预组和饮用水100mL组)及3个干预组(西甲硅油200mg组、西甲硅油联合N-乙酰半胱氨酸500mg组、西甲硅油联合N-乙酰半胱氨酸1000mg组),共纳入230例患者,女性占68%,平均年龄49岁,溶液于上消化道内镜检查前20分钟口服。
主要发现
- 可见度充分率在西甲硅油联合N-乙酰半胱氨酸500mg组为65%、1000mg组为67%,高于无干预组44%(P=0.044)和水组41%(P=0.022)。
- 胃总可见度量表评分在西甲硅油联合N-乙酰半胱氨酸500mg组和1000mg组均显著优于水组(P=0.03和P=0.008)。
- 西甲硅油组与无干预组和水组相比无差异。
- 西甲硅油联合N-乙酰半胱氨酸1000mg组改善可见度所需用水量更少。
- 未观察到研究药物相关的不良反应。
关键数值与推荐
- 胃可见度按先前描述的量表在4个节段评估,评分小于7分定义为可见度充分。
- 上消化道内镜最常见指征为上腹痛/消化不良(33%)。
临床怎么用
- 作者结论认为检查前使用西甲硅油联合N-乙酰半胱氨酸500mg或1000mg可改善上消化道内镜的可见度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: Upper GI endoscopy (UGE) is essential for the diagnosis of gastrointestinal diseases. Mucus and bubbles may decrease mucosal visibility. The use of mucolytics could improve visualization. Our aim was to determine whether premedication with simethicone or simethicone plus N-acetylcysteine is effective in improving visibility during UGE. METHODS: This was a randomized, double-blinded, placebo-controlled trial with 2 control groups: no intervention and water 100 mL (W); and 3 intervention groups: simethicone 200 mg (S); S + N-acetylcysteine (NAC) 500 mg (S+NAC500); and S + NAC 1000 mg (S+NAC1000). The solution was ingested 20 minutes before UGE. Gastric visibility was evaluated in 4 segments with a previously described scale. A score of less than 7 points was defined as adequate visibility (AV). Water volume was used to improve visibility, and adverse reactions were evaluated as a secondary outcome. Multiple group comparison was performed using non-parametric one-way analysis of variance (ANOVA). RESULTS: Two hundred thirty patients were included in the study, 68% female, mean age 49 years. The most common indication for UGE was epigastric pain/dyspepsia (33%). AV was more frequent in the S+NAC500 and S+NAC1000 groups (65% and 67%) compared with no intervention (44%, P = .044) and water (41%, P = .022). The gastric total visibility scale (TVS) was significantly better in the S+NAC500 and S+NAC1000 groups compared with water (P = .03 and P = .008). Simethicone was not different from no intervention and water. S+NAC1000 required less water volume to improve visibility. No adverse reactions from the study drugs were observed. CONCLUSIONS: Premedication with S+NAC500 and S+NAC1000 improves visibility during UGE. The use of simethicone did not show improvements in gastric visibility. TVS was worse in patients using water alone. (Clinical trial registration number: NCT 01653171.).
引用
- Monrroy H, Vargas JI, Glasinovic E, et al. Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial. Gastrointest Endosc. 2017. PMID: 29037773. doi:10.1016/j.gie.2017.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。